香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不作任何聲明，並明確表示概不就因本公告的全部或任何部分內容而 產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fangzhou Inc. 方舟云康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6086） 主席、首席執行官及授權代表變更； 董事重新委任； 及 提名委員會組成變更 方舟云康控股有限公司（「本公司」，連同其附屬公司及合併關聯實體， 「本集團」）董事（「董事」，各自為一名「董事」）會（「董事會」）謹此公 告， –1– 於本公告日期，根據證券及期貨條例（香港法例第571章）第XV部的規定，謝 先生於本公司合共711,449,830股股份中擁有權益。 除上述披露者外，於本公告日期，謝先生(i)在過往三年內並無在香港或海外 任何其他證券市場上市之公眾公司中擔任任何董事職位；(ii)並無其他主要 任命及資格；(iii)在本集團內並無擔任任何其他職位；(iv)與本公司任何其他 董事、高級管理人員或主要或控制股東並無任何關係；及(v)在證券及期貨 條例（香港法例第571章）第XV部的定義下，在本公司股份 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06086 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,340,267,457 | | 0 | | 1,340,267,457 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 1,340,267,457 | | 0 | | 1,340,267,457 | 公司名稱: 方舟云康控股有限公司 呈交日期: 2025年12月4日 I. 法定/註冊股本 ...

Core Viewpoint - The collaboration between Ark Health and Tencent Health marks a new development phase in the domestic chronic disease management sector, providing comprehensive support for technological validation, scenario implementation, and large-scale deployment in the industry [1][5]. Group 1: AI and Chronic Disease Management - The "AI + Chronic Disease Management" solution is based on Ark Health's effective practices in the field, demonstrating significant value through substantial business data, with a 2.4 times increase in AI function experience user volume in October [1][2]. - The AI technology effectively addresses user pain points, such as the common difficulty patients face in understanding medical reports, leading to increased user engagement and trust in the AI functionalities [2][3]. Group 2: Technical Foundation and Security Measures - The solution is built on a solid technical foundation, utilizing Tencent Health's TI platform to create a large model base, enabling efficient fine-tuning and continuous optimization of models [3][4]. - Ark Health has implemented multiple security measures to ensure reliable application in the sensitive medical field, including knowledge base optimization and compliance upgrades to mitigate risks associated with large models [2][3]. Group 3: Industry Collaboration and Policy Response - The partnership aims to integrate Ark Health's AI capabilities with Tencent Health's comprehensive service capabilities, facilitating safe, efficient, and compliant digital upgrades for industry partners [3][5]. - This collaboration aligns with recent policy initiatives from the National Health Commission and other departments to promote and regulate the application of AI in healthcare, positioning AI medical solutions as a vital component of public health infrastructure [5]. Group 4: Future Outlook - Ark Health plans to continue driving technological innovation and deepen collaborations with Tencent Health and other industry partners, aiming to enhance chronic disease management services towards greater efficiency, precision, and accessibility [5].

Core Insights - The collaboration between Ark Health (方舟健客) and Tencent Health marks a new development stage in chronic disease management in China, providing comprehensive support from technology validation to large-scale deployment [1] - The "AI + Chronic Disease Management" solution is based on Ark Health's effective practices and significant business data, showcasing a 2.4 times increase in AI feature user engagement in October [2] - The partnership aims to integrate Ark Health's AI capabilities with Tencent Health's robust service infrastructure to facilitate safe, efficient, and compliant digital upgrades in the healthcare industry [4][5] Group 1 - The "AI + Chronic Disease Management" solution is designed to address real user pain points, such as understanding medical reports, significantly increasing user engagement and trust in AI functionalities [2][3] - Ark Health's AI + H2H ecosystem, which includes a self-developed large model, provides a closed-loop service system covering the entire chronic disease management cycle [3] - The collaboration is a response to national policies promoting the integration of AI in healthcare, aiming to contribute to the "Healthy China 2030" strategy [6] Group 2 - The solution leverages Ark Health's deep understanding of internet medical service scenarios and Tencent Health's stable and secure technical infrastructure [5] - The partnership emphasizes the importance of safety and compliance, utilizing Tencent Health's intelligent security measures to protect sensitive data in medical applications [4] - Future plans include continued technological innovation and collaboration with industry partners to enhance chronic disease management services [6]

Core Insights - The collaboration between Ark Health (方舟健客) and Tencent Health marks a new development stage in chronic disease management in China, focusing on an "AI + Chronic Disease Management" solution [1][6] - The partnership aims to provide comprehensive support from technology validation to large-scale deployment, enhancing the industry's intelligent, compliant, and efficient development [1][7] Group 1: Company Strengths - Ark Health is recognized as a leading "AI + Chronic Disease Management" service platform, leveraging its innovative "AI + H2H (Hospital to Home) smart medical ecosystem" to establish unique technological advantages and practical experience in chronic disease management [1][5] - Tencent Cloud is a prominent cloud service provider with strengths in cloud computing, big data, and artificial intelligence, complementing Ark Health's capabilities [1][6] Group 2: Solution Features - The "AI + Chronic Disease Management" solution is based on Ark Health's effective practices in the field, with significant growth demonstrated by a 2.4 times increase in AI function experience user volume in October [4] - The solution integrates AI technology to address real user pain points, such as the "report interpretation" feature in the JianKe Doctor APP, which has increased user engagement and trust [4][5] Group 3: Technical Infrastructure - The solution is built on a solid technical foundation, utilizing Tencent Health's TI platform for model development and optimization, and incorporating a vector database for rapid semantic retrieval [7][8] - Security and compliance are prioritized through the implementation of detailed safety strategies, ensuring the protection of sensitive data and compliance with industry regulations [7][8] Group 4: Industry Impact - This collaboration represents a significant exploration of the integration of artificial intelligence and healthcare, responding to recent policy initiatives aimed at promoting AI in the medical sector [8][9] - Ark Health aims to continue driving innovation and collaboration to enhance chronic disease management services, contributing to the "Healthy China 2030" strategic goals [9]

Core Insights - Fangzhou Inc. and Tencent Healthcare have launched an "AI+Chronic Disease Management" solution, enhancing the integration of AI in China's healthcare sector [1][4][7] - The solution leverages Fangzhou's AI+H2H ecosystem and Tencent Cloud's technological capabilities, aiming to improve chronic disease management efficiency [2][6] - The partnership aligns with national health guidelines and supports the "Healthy China 2030" initiative, promoting digital transformation in healthcare [7] Company Overview - Fangzhou Inc. is a leading online chronic disease management platform in China, with 52.8 million registered users and 229,000 physicians as of June 30, 2025 [9] - The company specializes in AI-enabled precision medicine solutions and tailored medical care [9] Technological Framework - The solution is built on a robust technological foundation, utilizing Tencent Healthcare's TI platform for model training, evaluation, and deployment [6] - Tencent's vector database enhances the accuracy of medical knowledge retrieval, supporting the AI's factual outputs [6] Safety and Compliance - Fangzhou has implemented multiple safety measures to mitigate AI hallucinations in clinical settings, including reinforcement learning and rule-based supervision [5][6] - Compliance with regulatory standards for clinical AI is ensured through Tencent Healthcare's AI security measures [6]

Core Insights - Fangzhou Inc. and Tencent Healthcare have launched a comprehensive "AI+Chronic Disease Management" solution, marking a significant advancement in the application of AI in China's healthcare sector [1][6] - The solution integrates Fangzhou's AI+H2H ecosystem with Tencent Cloud's technological capabilities, aiming to enhance chronic disease management through intelligent service delivery [2][5] Company Overview - Fangzhou Inc. is a leading online chronic disease management platform in China, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025 [9] - The company specializes in tailored medical care and AI-enabled precision medicine solutions [9] Strategic Collaboration - The partnership combines Fangzhou's expertise in healthcare with Tencent Healthcare's industrial-grade infrastructure, aiming to set a new standard for chronic disease management in China [3] - Tencent Healthcare provides a robust technological foundation, leveraging its capabilities in cloud computing, big data, and AI to support the transformation of chronic disease management [2][5] Technological Framework - The solution is built on Tencent Healthcare's TI platform, which enables continuous model optimization through one-stop training, evaluation, and deployment pipelines [5] - Tencent's vector database enhances the accuracy of medical knowledge retrieval, supporting the solution's compliance with regulatory standards for clinical AI [5] Compliance and Safety - Fangzhou emphasizes safety and compliance, implementing multiple layers of protection against AI hallucinations in clinical settings [4] - The partnership aligns with the National Health Commission's guidelines for developing safe "AI + healthcare" applications, supporting long-term national health goals under the "Healthy China 2030" initiative [6]

Core Insights - The core theme of the conference was "Collaborative Win-Win: Smartly Leading the Future," focusing on enhancing chronic disease management through artificial intelligence [1][2] - The strategic partnership between Fangzhou Jianke and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. aims to explore innovative approaches in the health industry empowered by AI [1][6] Industry Trends - The National Health Commission issued guidelines promoting the application of AI in healthcare, outlining core goals and pathways for the next five years [2] - The aging population and the increasing prevalence of chronic diseases in younger demographics highlight the critical role of AI technology in healthcare [2] Company Developments - Fangzhou Jianke's CEO, Dr. Xie Fangmin, emphasized the importance of addressing real problems and driving genuine change in chronic disease management through AI [2][4] - The user engagement with the "AI Health Steward" platform has significantly increased, with user numbers in October being 2.4 times that of September and GMV rising by 50% [4] Strategic Collaborations - The partnership with Wangshan Wangshui is designed to integrate technological empowerment with product pipeline advantages, aiming for a comprehensive upgrade from drug supply to health services [6][8] - Both companies plan to create replicable and scalable AI-driven solutions for chronic disease management, enhancing the quality of development in the health industry [5][6]

Core Insights - The core theme of the conference was "Collaborative Win-Win: Smartly Leading the Future," focusing on enhancing chronic disease management through artificial intelligence [1][2] Group 1: Strategic Partnerships - Ark Health and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. announced a strategic cooperation aimed at integrating core industry resources with digital technology capabilities [1][5] - The partnership is designed to break down industry barriers and achieve a full-chain upgrade from drug supply to health services [5][6] Group 2: AI and Chronic Disease Management - The Chinese government has emphasized the importance of "AI + healthcare," providing a clear direction for the industry's development over the next five years [2][4] - Ark Health's CEO highlighted the critical role of AI in addressing the challenges posed by an aging population and the increasing prevalence of chronic diseases [2][4] Group 3: Technological Advancements - The application of AI technology has led to significant user engagement, with a 2.4 times increase in users experiencing AI features in October compared to September, and a 50% increase in GMV [4] - The company aims to create replicable and scalable AI-driven solutions for chronic disease management, enhancing the quality of health services [4][6] Group 4: Future Outlook - The collaboration is expected to enhance the alignment between biopharmaceutical research and health service delivery, ensuring that research outcomes meet user needs more effectively [6] - Ark Health plans to continue deepening its focus on chronic disease management and strengthening its technological foundation to drive the digital transformation of health services [6]

Core Insights - The article discusses the successful convening of the Ark Health (方舟健客) Double 12 Core Partner Summit, focusing on the theme "Collaborative Win-Win, Intelligent Future," which gathered key players in the internet healthcare industry to explore the enhancement of chronic disease management through artificial intelligence [1][2] - A strategic partnership was announced between Ark Health and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. (旺山旺水), aimed at integrating core industry resources with digital technology capabilities to drive innovation in the health industry [1][6] Industry Trends - The Chinese government has emphasized the importance of "AI+" initiatives across various sectors, including healthcare, as part of its strategic direction for the next five years [1][2] - The aging population and the increasing prevalence of chronic diseases among younger individuals highlight the critical role AI technology can play in healthcare [2] Company Developments - Ark Health's CEO, Dr. Xie Fangmin, highlighted the company's commitment to addressing real problems and delivering tangible changes in chronic disease management through AI applications [2][5] - The company reported a significant increase in user engagement with its AI features, with a 2.4 times increase in users experiencing AI functionalities and a 50% rise in Gross Merchandise Volume (GMV) in October compared to September [4] Strategic Collaboration - The partnership between Ark Health and Wangshan Wangshui is designed to break down industry barriers and integrate technological empowerment with product pipeline advantages, facilitating a comprehensive upgrade from drug supply to health services [5][6] - Both companies aim to create a customer-centric health service system, providing tailored, efficient, and professional health management solutions throughout the entire lifecycle [6][8] Future Outlook - The collaboration is expected to enhance the connection between biopharmaceutical research and health services, ensuring that research outcomes align more closely with user needs [8] - Ark Health plans to continue its focus on chronic disease management, strengthening its technological foundation and enhancing application scenarios to promote digital transformation in health services [9]